- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04785209
Mean Platelet Volume and STEMI Clinical Risk Scores in Prediction of Impaired Myocardial Perfusion In Acute STEMI Patients Undergoing Primary Percutaneous Coronary Intervention.
March 2, 2021 updated by: Andrew Reymon Sadik Salama, Assiut University
Mean Platelet Volume and STEMI Clinical Risk Scores in Prediction of Impaired Myocardial Perfusion In Acute STEMI Patients Undergoing PPCI.
Predicting no reflow in ppci of STEMI patients using mean platelet volume together with STEMI clinical risk scores
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Anticipated)
84
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Andrew Salama, Resident
- Phone Number: +201210999130
- Email: Andrew.rey@hotmail.com
Study Contact Backup
- Name: Shaimaa Khedr, Assistant lecturer
- Phone Number: +201001346551
Study Locations
-
-
-
Assiut, Egypt, 71515
- Recruiting
- Assiut University Hospital
-
Contact:
- Andrew Salama
- Phone Number: +201210999130
- Email: andrew.rey@hotmail.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
N/A
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
All STEMI patients presenting within 24 hrs of onset of symptoms
Description
Inclusion Criteria:
- patients presenting with acute STEMI, within 24 hours of symptoms, fulfilling criteria for PPCI protocol in our facility
Exclusion Criteria:
- patients presenting more than 24 hours of symptoms onset
- patients not eligible for PPCI program in our facility
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Cross-Sectional
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
No complication
Thrombolysis in myocardial infarction flow grade III flow after PPCI, mean platelet volume, lymphocyte ratio, detailed echo within 24 hrs of admission, clinical STEMI risk scores
|
Lab parameters
|
No reflow
No reflow phenomenon after pci on STEMI patients, mean platelet volume, lymphocyte ratio, detailed echo within 24 hrs of admission, clinical STEMI risk scores
|
Lab parameters
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participents with No reflow after PPCI and in hospital mortality
Time Frame: Within 48 hours from admission
|
No reflow: suboptimal myocardial reperfusion through a part of coronary circulation without angiographic evidence of mechanical vessel obstruction. In hospital mortality |
Within 48 hours from admission
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Hamdy Shams elddin, Professor, Assiut University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
March 1, 2021
Primary Completion (Anticipated)
March 1, 2023
Study Completion (Anticipated)
March 1, 2023
Study Registration Dates
First Submitted
September 23, 2020
First Submitted That Met QC Criteria
March 2, 2021
First Posted (Actual)
March 5, 2021
Study Record Updates
Last Update Posted (Actual)
March 5, 2021
Last Update Submitted That Met QC Criteria
March 2, 2021
Last Verified
March 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Prediction of No reflow
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on No-Reflow Phenomenon
-
Hull University Teaching Hospitals NHS TrustCompletedSTEMI | No Reflow PhenomenonUnited Kingdom
-
Assiut UniversityNot yet recruiting
-
Ain Shams UniversityNot yet recruitingNo-Reflow Phenomenon
-
TC Erciyes UniversityCompleted
-
Universität Duisburg-EssenUnknownCoronary Heart Disease | Coronary Arteriosclerosis | No Reflow PhenomenonGermany
-
Instituto Nacional de Cardiologia Ignacio ChavezNot yet recruitingSTEMI | No-Reflow Phenomenon
-
First Hospital of China Medical UniversityAstraZenecaUnknownMyocardial Infarction | No-Reflow PhenomenonChina
-
Privolzhsky Research Medical UniversityCompletedMyocardial Infarction | No-Reflow PhenomenonRussian Federation
-
RenJi HospitalCompletedST Segment Elevation Myocardial Infarction | Coronary Slow Flow PhenomenonChina
-
National Institute of Cardiovascular Diseases,...CompletedAcute Coronary Syndrome | No-Reflow Phenomenon | NormotensivePakistan
Clinical Trials on Mean platelet volume, lymphocyte number, STEMI clinical risk scores
-
Ankara UniversityCompletedCardiac Disease
-
Sohag UniversityCompleted